Collaborations between Immodulon Therapeutics and academic laboratories in London Universities are yielding new data showing promising therapeutic effects of treatment with IMM-101 (a heat-killed whole cell preparation of Mycobacterium obuense NCTC13365) in various preclinical models of cancer. Preliminary data were presented at the 2013 and 2014 Annual meeting of the Society for Immunotherapy (SITC).
Full Title: Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer.
Journal: Journal of ImmunoTherapy of Cancer
Authors: Androulla Elia, Louise Lincoln, Laura Rosa Brunet and Thorsten Hagemann
DOI: 10.1186/2051-1426-1-S1-P215
Date: 7 November 2013
Full Title:
Journal: Journal of ImmunoTherapy of Cancer
Authors: Daniel Fowler, Angus Dalgleish and Wai Lu
DOI: 10.1186/2051-1426-2-S3-P54
Date: 6 November 2014